Partial
Partially Aligned
Patient Risk:
Medium
Summary
Several factual statements (mechanism class and storage 'protect from light and moisture') align with the provided label text, but many other claims are unsupported (expiration guidance, post-expiration safety/risks, degradation extent from studies/sources, and sensitivity to heat/moisture details not supported). Indications/usage for high blood pressure and angina are not verifiable from the supplied label excerpt.
Category Scores
Accurate Statements
Amlodipine is a calcium channel blocker.
Mechanism of Action excerpt describes amlodipine as a dihydropyridine calcium antagonist/slow-channel blocker.
Exposure to light, heat, and moisture can cause amlodipine to degrade faster.
The provided 'HOW SUPPLIED' text includes 'Protect from light and moisture' (does not mention heat).
Bottles with tight-fitting lids or foil-lined blister packs can help protect amlodipine from light and moisture.
Not explicitly supported in the provided label excerpt; only 'Protect from light and moisture' is stated.
Amlodipine stored in a dark place can still be taken.
Not explicitly supported; label excerpt only states 'Protect from light and moisture' and provides storage temperature ranges.
Unsupported Statements
Amlodipine is used for high blood pressure.
The provided label excerpt does not include the Indications and Usage section text.
Amlodipine is used for angina.
The provided label excerpt does not include the Indications and Usage section text (only mechanism mentions angina in the mechanism discussion).
The expiration date on amlodipine tablets or capsules is a guideline set by the manufacturer to indicate the last date the product is guaranteed to be at its peak potency and effectiveness.
No expiration-date explanation is provided in the supplied label excerpt.
Amlodipine does not become useless or even slightly less effective immediately after the expiration date.
No post-expiration performance statements are provided in the supplied label excerpt.
Amlodipine is sensitive to light.
Not explicitly stated as 'sensitive to light'; the label excerpt says 'Protect from light and moisture.'
Amlodipine is sensitive to heat.
The label excerpt provides temperature storage conditions but does not state 'sensitive to heat' or degradation from heat exposure.
Amlodipine is sensitive to moisture.
The label excerpt says 'Protect from light and moisture' but does not state 'sensitive to moisture' as such.
Improper handling, such as exposure to extreme temperatures or physical stress, can affect amlodipine's shelf life.
No shelf-life/handling guidance beyond 'Store at 20°-25°C' with excursions and 'Protect from light and moisture' is provided.
According to the FDA, most medications, including amlodipine, are still safe to use after the expiration date.
No FDA post-expiration safety statement is provided in the supplied label excerpt.
After the expiration date, amlodipine potency may decrease over time.
No post-expiration potency statement is provided in the supplied label excerpt.
A study in the Journal of Pharmaceutical Sciences found that amlodipine potency decreased by 10% to 20% after 24 months of storage at room temperature.
No such study or quantitative potency-loss data is provided in the supplied label excerpt.
A source (DrugPatentWatch.com) states that amlodipine's shelf life is typically 2 to 3 years from the date of manufacture.
No shelf-life source or duration statement is provided in the supplied label excerpt.
Taking amlodipine after its expiration date may not cause immediate harm.
No post-expiration harm guidance is provided in the supplied label excerpt.
If taken after the expiration date, decreased amlodipine potency may lead to reduced effectiveness.
No post-expiration effectiveness statement is provided in the supplied label excerpt.
Reduced effectiveness from decreased potency may lead to inadequate blood pressure control.
No post-expiration effectiveness statement is provided in the supplied label excerpt.
Reduced effectiveness from decreased potency may lead to inadequate angina symptom control.
No post-expiration effectiveness statement is provided in the supplied label excerpt.
If taken after the expiration date, decreased amlodipine potency can cause an increase in side effects.
No post-expiration side-effect statement is provided in the supplied label excerpt.
Side effects that may increase with decreased potency include dizziness, headache, or swelling.
While the label excerpt lists headache/edema and dizziness as adverse events during therapy, it does not support that they 'increase with decreased potency' or post-expiration use.
Amlodipine expiration date is a guideline, not a hard and fast rule.
No expiration-date policy language is provided in the supplied label excerpt.
Proper storage and handling procedures are essential to ensure amlodipine remains effective and safe to use.
The label excerpt provides storage instructions ('Store at...' and 'Protect from light and moisture') but does not include effectiveness/safety framing about handling.
Typically, amlodipine can be taken 2 to 3 years from the date of manufacture after expiration.
No such timing guidance is provided in the supplied label excerpt.
Amlodipine stored in a hot or humid environment should not be taken.
The label excerpt provides specific storage temperatures and says 'Protect from light and moisture,' but does not state an instruction not to take based on 'hot or humid environment.'
Contradictions
Low
AI Statement
Improper handling, such as exposure to extreme temperatures or physical stress, can affect amlodipine's shelf life.
Label Reference
HOW SUPPLIED excerpt only states 'Store at 20°-25°C; excursions permitted to 15°-30°C' and 'Protect from light and moisture' without addressing physical stress or 'shelf life' impact.
Important Omissions
If an AI response included dosing/administration directions, these were not provided in the supplied label excerpt. (However, the current set of claims contains no dosing instructions.)
Importance:
Low
Contraindications/boxed warnings/warnings-precautions content were not evaluated because the provided AI claims did not address them.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Medium
The most safety-relevant issues are unsupported post-expiration-use assertions (safety, harm timing, effectiveness and side-effect increases) that are not supported by the provided label excerpts.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Partially Aligned
Primary Issue
Major unsupported claims about expiration-date meaning and post-expiration safety/effectiveness are not supported by the provided label text.
Suggested Improvement
Limit claims to what is present in the provided label excerpt (e.g., calcium antagonist/slow-channel blocker mechanism and storage instructions: 'Store at 20°-25°C' with excursions and 'Protect from light and moisture'); remove quantitative study/source statements and any assertions about using after expiration date unless explicitly supported by the provided prescribing information.